WARSAW, Ind., Aug. 2 /PRNewswire-FirstCall/ -- Symmetry Medical Inc. , an independent provider of products to the global orthopedic device industry, announced today second quarter 2006 financial results for the period ended July 1, 2006.
The Company reported second quarter 2006 revenue of $64.8 million, a decrease of 7.7% over the second quarter of 2005. The Company’s second quarter revenue includes $3.4 million from Riley Medical, which was acquired by the Company in May of 2006.
Gross profit for the second quarter of 2006 was $16.9 million, a 21.2% decrease from gross profit of $21.4 million for the second quarter of 2005. Gross margin for the second quarter 2006 was 26.1%, compared to a gross margin of 30.6% for the second quarter 2005. The lower gross margin rate was primarily a result of higher fixed costs from the 2005 expansion across the Company’s global facilities and reflects sales reductions, which were more pronounced in the higher margin products within each of the Company’s product segments.
Operating income for the second quarter of 2006 was $10.0 million, a 32.0% decrease over operating income of $14.7 million for the second quarter of 2005. Operating margin for the second quarter 2006 was 15.4%, compared to an operating margin of 20.9% for the second quarter 2005.
Income before income taxes for the second quarter of 2006 was $10.7 million, a 17.8% decrease over income before income taxes of $13.0 million for the second quarter of 2005. Second quarter 2006 income before income taxes included a $1.2 million gain on the sale of surplus land adjacent to the Company’s Sheffield, UK facility.
Net income for the second quarter 2006 was $7.7 million, or $0.22 per diluted share, compared to a net income of $8.6 million, or $0.25 per diluted share, for the second quarter 2005. This includes an Indiana Edge tax credit benefit of $0.3 million.
The weighted average number of diluted shares outstanding during the second quarter of 2006 was 35,177,000.
Brian Moore, President and Chief Executive Officer, stated, “Our revenue was impacted by the slowdown in demand for major orthopaedic joints throughout the industry. Because of Symmetry’s position in the supply chain for these joints, we were affected disproportionately by these industry developments. These results were further impacted by reduced customer product launches. We are taking advantage of this slower period to extend our ‘Total Solutions’ approach into other markets, as well as to increase acquisition activity. We believe that the Company remains very well positioned to respond to the upturn.”
Mr. Moore continued, “While the current market conditions impact the entire supply chain in orthopedic devices, we remain confident that Symmetry will continue as the leading provider to the orthopedic market.”
Financial Guidance
The following estimates regarding 2006 earnings guidance are based on current market conditions and foreign currency comparisons and are forward- looking. Actual results may differ materially and we refer you to the statement on forward-looking statements that appears at the end of the release.
For the full year 2006, the Company now expects revenue to be in the range of $260 million to $265 million. The Company expects full year 2006 earnings per diluted share in the range of $0.74 to $0.77.
Conference Call
Symmetry Medical will host a conference call at 8:00 a.m. EDT on Thursday, August 3, 2006. A live webcast of the conference call will be available online from the investor relations page of the Company’s corporate website at www.symmetrymedical.com. The dial-in numbers are (866) 700-7101 for domestic callers and (617) 213-8837 for international callers. The reservation number for both is 65747430. After the live webcast, the call will remain available on Symmetry’s website until August 31, 2006. In addition, a telephonic replay of the call will be available until August 17, 2006. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 97084244.
About Symmetry Medical Inc.
Symmetry Medical Inc. is an independent provider of implants and related instruments and cases to the orthopaedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including dental, osteobiologic and endoscopy sectors and provides limited specialized products and services to non- healthcare markets, such as the aerospace market.
Forward-Looking Statements
Statements in the press release regarding Symmetry Medical Inc.'s business, which are not historical facts, may be “forward-looking statements” that involve risks and uncertainties, within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such predictive statements are not guarantees of future performance, and actual results could differ materially from our current expectations. Certain factors that could cause actual results to differ include: the loss of one or more customers; the development of new products or product innovations by our competitors; product liability; changes in management; changes in conditions effecting the economy, orthopedic device manufacturers or the medical device industry generally; and changes in government regulation of medical devices and third-party reimbursement practices. We refer you to the “Risk Factors” and “Forward Looking Statements” sections in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as well as the Company’s other filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Symmetry Medical Inc. Consolidated Statements of Operations Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2006 2005 2006 2005 (In Thousands, Except Per Share Data) (unaudited) Revenue $64,760 $70,177 $134,373 $133,937 Cost of Revenue 47,873 48,735 97,145 93,108 Gross Profit 16,887 21,442 37,228 40,829 Selling, general, and administrative expenses 6,892 6,754 13,932 13,702 Operating Income 9,995 14,688 23,296 27,127 Other (income) expense: Interest expense 925 773 1,586 1,712 Derivatives valuation (gain)/loss 408 189 407 (107) Other (2,059) 681 (2,280) 883 Income before income taxes 10,721 13,045 23,583 24,639 Income tax expense 3,042 4,426 7,526 8,356 Net income applicable to common shareholders $7,679 $8,619 $16,057 $16,283 Net income (loss) applicable to common shareholders per share: Basic $0.22 $0.26 $0.46 $0.49 Diluted $0.22 $0.25 $0.46 $0.47 Weighted average common shares and equivalent shares outstanding: Basic 34,830 33,239 34,774 33,207 Diluted 35,177 34,477 35,157 34,296 Symmetry Medical Inc. Consolidated Balance Sheets July 1, December 31, 2006 2005 (In Thousands, Except Per Share Data) (unaudited) Assets: Current Assets: Cash and cash equivalents $10,686 $12,471 Accounts receivables, net 49,667 44,908 Inventories 43,942 38,783 Refundable income taxes 145 185 Deferred income taxes 2,166 1,867 Derivative valuation asset - 414 Other current assets 4,119 4,032 Total current assets 110,725 102,660 Property and equipment, net 101,688 93,106 Derivative valuation asset 477 170 Goodwill 153,392 124,518 Intangible assets, net of accumulated amortization 27,537 16,327 Other assets 1,066 864 Total Assets $394,885 $337,645 Liabilities and Shareholders’ Equity: Current Liabilities: Accounts payable $16,219 $18,983 Accrued wages and benefits 8,567 10,997 Derivative valuation liability 300 - Other accrued expenses 3,606 2,696 Income tax payable 725 1,241 Revolving line of credit 2,371 - Current portion of capital lease obligations 3,017 3,239 Current portion of long-term debt 2,150 1,313 Total current liabilities 36,955 38,469 Deferred income taxes 11,691 11,139 Capital lease obligations, less current portion 6,826 8,532 Long-term debt, less current portion 62,350 26,250 Total Liabilities 117,822 84,390 Shareholders’ Equity: Common Stock, $.0001 par value; 72,410 shares authorized; shares issued (July 1, 2006--34,894; December 31, 2005--34,704) 3 3 Additional paid-in capital 270,794 268,973 Retained earnings (deficit) (1,321) (17,378) Accumulated other comprehensive income 7,587 1,657 Total Shareholders’ Equity 277,063 253,255 Total Liabilities and Shareholders’ Equity $394,885 $337,645 Investors/Media: The Ruth Group Stephanie Carrington/Jason Rando 646-536-7017/7025 scarrington@theruthgroup.comjrando@theruthgroup.com Contact: Symmetry Medical Inc. Andrew Miclot Senior Vice President Marketing, Sales & Business Development Investor Relations Officer 574-269-7390 ext. 1002
Symmetry Medical Inc.
CONTACT: Investors/Media: Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group; or Andrew Miclot, SeniorVice President, Marketing, Sales & Business Development, Investor RelationsOfficer of Symmetry Medical Inc., +1-574-269-7390 ext. 1002
Web site: http://www.symmetrymedical.com/
